Neuphoria FY26 loss widens to $13.59 million; revenue drops 92.5% to $1.17 million
Neuphoria posted a pre-tax loss of USD 13.59 million, widening from USD 0.84 million a year earlier. Revenue fell 92.5% to USD 1.17 million, versus a year-ago period that included a USD 15 million Merck milestone. Research and development expense dropped 60.6% to USD 3.55 million, while general and administrative costs